NVO - Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness Study Reveals | Benzinga
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy (semaglutide).
The study, presented at the Digestive Disease Week meeting in Washington, found a 95% likelihood that patients with this genetic profile would be strong responders to the treatment.
Related: Changing Frugal Eating Habits-How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending.
The study involved 84 patients prescribed Wegovy for obesity.
Those with the genetic variants associated with a “hungry gut” lost an average of 14.4% of their body weight after nine months and 19.5% after a year.
By comparison, participants without ...